RÉSUMÉ
Objective To explore the efficacy and safety of antiplatelet therapy in patients with acute ischemic stroke(AIS)complicated with gastric cancer.Methods Clinical data of 89 patients with AIS complicated with gastric cancer who were hospitalized in the First People's Hospital of Huzhou from January 2018 to October 2022 were retrospectively analyzed.The patients were divided into treatment group(59 cases)and untreated group(30 cases)according to whether they received antiplatelet therapy or not,and the clinical characteristics and prognosis of the two groups were compared.To analyze the clinical features and influencing factors of gastrointestinal bleeding complicated by antiplatelet therapy in AIS patients with gastric cancer.Results The patients in treatment group were younger than those in untreated group,and had more history of antiplatelet therapy,hypertension and cardiovascular disease,the difference was statistically significant(P<0.05).The National Institute of Health stroke scale(NHISS)and modified Rankin scale(mRs)of patients in treatment group were lower than those in untreated group after antiplatelet therapy,the difference was statistically significant(P<0.05).The incidence of bleeding in treated group was significantly higher than that in untreated group(P<0.05),most of the patients had mild hemoglobin decline.Multivariate Logistic analysis suggested that chronic renal insufficiency,gastric cancer lesion diameter≥2cm and T1-T2 stage are risk factors for gastrointestinal bleeding in AIS patients with gastric cancer after taking aspirin for antiplatelet therapy.Conclusion In AIS patients with gastric cancer,aspirin antiplatelet therapy can effectively improve cerebrovascular function and reduce the degree of brain nerve damage.However,when these patients are combined with T1-T2 stage,chronic renal insufficiency and gastric cancer lesion diameter≥2cm,gastrointestinal bleeding is easy to occur.
RÉSUMÉ
Objective:To investigate the application value of pepsinogen, Helicobacter pylori combined with endoscopic Kimura-Takemoto classification in the diagnosis of early gastric cancer. Methods:Sixty patients with gastric cancer who received treatment in the Department of Gastroenterology, the First People's Hospital of Huzhou from January to June 2022 were included in the gastric cancer group. An additional 60 patients with benign gastric lesions (benign gastric lesion group) and 60 patients with precancerous lesions of the stomach (precancerous lesion group) were also included in this study. Serologic testing for pepsinogen and Helicobacter pylori antibody combined with endoscopic Kimura-Takemoto classification was performed to evaluate their application value in the diagnosis of early gastric cancer. Results:Compared with the benign gastric lesion and precancerous lesion groups, the pepsinogen I/pepsinogen II ratio was significantly lower, and the pepsinogen II level and Helicobacter pylori infection rate [71.67% (43/60)] were significantly higher in the gastric cancer group ( F = 108.14, 71.75, 38.43, χ2 = 6.89, all P < 0.05). Compared with the benign gastric lesion and precancerous lesion groups, the Kimura-Takenmoto classification in the gastric cancer group was significantly higher ( H = 38.91, P < 0.05). In the gastric cancer group, pepsinogen I level and pepsinogen I/pepsinogen II ratio decreased and pepsinogen II level increased with the increase of pathological stage ( F = 65.79, 5.66, 53.32, all P < 0.01). There was no significant difference in Helicobacter pylori infection rate between different stages of gastric cancer ( P < 0.05) in the gastric cancer group. There was no significant difference in Kimura-Takenmoto classification between different stages of gastric cancer (all P > 0.05) in the gastric cancer group. The area under the receiver operating characteristic curve plotted for evaluating pepsinogen I, pepsinogen II, and pepsinogen I/pepsinogen II ratio for diagnosis of gastric cancer was 0.865, 0.664, and 0.881, respectively. Conclusion:Serum pepsinogen, Helicobacter pylori combined with endoscopic Kimura-Takemoto classification can increase the diagnostic rate of early gastric cancer. The Kimura Takemoto classification is helpful for risk stratification in the endoscopic screening of gastric cancer, and its results are consistent with pepsinogen levels. The combined application is of a high application value.
RÉSUMÉ
Objective To explore the expression of HCCR, pERK and pELK1 in gastric cancer tissue and para-carci-noma tissue, and to explove its correlations. Methods In 60 human gastric cancers and their corresponding paraneo-plastic tissuses,the expression of HCCR, pERK and pELK1 were detected by immunohistochemistry. Results The ex-pression of HCCR was 75.0%(45/60), pERK, and pELK1 were 73.3%(44/60) and 71.7%(43/60), respectively, and the expression of proteins in gastric tumor were higher than that in paraneoplastic tissues (P<0.05). Conclusion The HCCR, pERK and pELK1 are higher expressed in tumor tissues, availably as a auxiliary index for clinical immunohis-tochemistry in gastric cancer.
RÉSUMÉ
Human cervical cancer oncogene(HCCR) is newly identified in cervical cancer tissues,and expresses in most human tumors. Resarches show that HCCR is a candidate marker for human hepatocelular carcinoma and breast cancer. Moreover,the expression of HCCR is regulated by mitogen-activated protein kinase (MAPK)and phosphatidylinositol 3-kinase signal pathway. The proliferation,apoptosis,migration and invasion of tumor cells could be inhibited by siRNA of HCCR.
RÉSUMÉ
0 (P<0.01).Conclusions HERG1 was over expressed in PANC1 cells and tissues of human pancreatic cancer.The HERG1 K+ channel was related to the proliferation,migration and invasion of PANC1.